HDAC9 and acute myeloid leukemia: In agreement with our findings, Nishiokaet al. [29] showed that the HDAC inhibitor MS-275 was able to block Akt/mTOR signaling in acute myelogenous leukemia HL60 cells and acute promyelocytic leukemia cells.